References
- Kang Y, Jo EJ, Eom JS, Kim MH, Lee K, Kim KU, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-public-private mix periods. Tuberc Respir Dis 2021;84:74-83. https://doi.org/10.4046/trd.2020.0093
- Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, et al. Culture conversion in patients treated with bedaquiline and/or delamanid: a prospective multicountry study. Am J Respir Crit Care Med 2021;203:111-9. https://doi.org/10.1164/rccm.202001-0135OC
- Ministry of Health of Indonesia Republic. Programmatic management of drug resistance tuberculosis 2011-2014 [Internet]. Jakarta: Ministry of Health of Indonesia Republic; 2016 [cited 2021 Jul 20]. Available from: https://www.who.int/docs/default-source/searo/indonesia/non-who-publications/programmatic-management-of-drug-resistance-tb-inindonesia-2011-2014-bahasa.pdf?sfvrsn=aa2e3df1_2.
- Guglielmetti L, Jaspard M, Le Du D, Lachatre M, MarigotOuttandy D, Bernard C, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017;49:1601799. https://doi.org/10.1183/13993003.01799-2016
- Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: a retrospective cohort study. PLoS One 2021;16:e0246284. https://doi.org/10.1371/journal.pone.0246284
Cited by
- Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply vol.85, pp.1, 2021, https://doi.org/10.4046/trd.2021.0135